- Investing Ideas
- /
- Top Growth Stocks
Top Global Pharmaceuticals & Biotech Growth Stocks
UPDATED Jul 03, 2022
What are the best Global Pharmaceuticals & Biotech Growth Stocks?
According to our Simply Wall St analysis these are the best Global Pharmaceuticals & Biotech growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.
Our criteria to find Top Growth Companies
Growth
- Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.
What do we look for?
- Is the company forecast to have high earnings growth.
Healthy Balance Sheet
- A healthy balance sheet is essential to drive growth opportunities and sustain the business.
- Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.
What do we look for?
- Does the company have a manageable level of debt.
- Is the company able to cover its interest repayments.
81 companies meet this criteria in the Global market
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: CALTX is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 98.5% below our estimate of its fair value
Earnings are forecast to grow 60.26% per year
Risks
Shareholders have been diluted in the past year
Volatile share price over the past 3 months
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: CUV's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 30.4% below our estimate of its fair value
Earnings are forecast to grow 29.38% per year
Earnings grew by 15.2% over the past year
Risks
Significant insider selling over the past 3 months
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: CAMX is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 82.8% below our estimate of its fair value
Earnings are forecast to grow 52.56% per year
Earnings have grown 4.8% per year over the past 5 years
Risks
No risks detected for CAMX from our risks checks.
Zhejiang Starry Pharmaceutical Co.,Ltd. engages in the research and development, production, and sale of X-CT non-ionic contrast agents and fluoroquinolones drugs and intermediates in China and internationally.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: 603520's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Price-To-Earnings ratio (28.4x) is below the CN market (34.2x)
Earnings are forecast to grow 31.85% per year
Earnings grew by 31.7% over the past year
Risks
Has a high level of debt
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: 300009's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 68.6% below our estimate of its fair value
Earnings are forecast to grow 40.23% per year
Risks
Profit margins (11.5%) are lower than last year (21.5%)
Large one-off items impacting financial results
Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: GENO's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 57.2% below our estimate of its fair value
Earnings are forecast to grow 55.56% per year
Earnings grew by 299.3% over the past year
Risks
No risks detected for GENO from our risks checks.
Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: ALVAL is expected to become profitable in the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 96.8% below our estimate of its fair value
Earnings are forecast to grow 100.72% per year
Risks
Makes less than USD$1m in revenue (€298K)
Does not have a meaningful market cap (€59M)
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
Growth Criteria
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings: 603392's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market
High Growth Revenue
Future ROE
Rewards
Trading at 37.5% below our estimate of its fair value
Earnings are forecast to grow 26.7% per year
Earnings grew by 242% over the past year
Risks
High level of non-cash earnings